| Literature DB >> 21235753 |
Sebastian Boltaña1, Felipe Reyes-Lopez, Davinia Morera, Frederick Goetz, Simon A MacKenzie.
Abstract
BACKGROUND: Pathogen-associated molecular patterns (PAMPs) are structural components of pathogens such as lipopolysaccharide (LPS) and peptidoglycan (PGN) from bacterial cell walls. PAMP-recognition by the host results in an induction of defence-related genes and often the generation of an inflammatory response. We evaluated both the transcriptomic and inflammatory response in trout (O. mykiss) macrophages in primary cell culture stimulated with DAP-PGN (DAP; meso-diaminopimelic acid, PGN; peptidoglycan) from two strains of Escherichia coli (PGN-K12 and PGN-O111:B4) over time.Entities:
Mesh:
Substances:
Year: 2011 PMID: 21235753 PMCID: PMC3087353 DOI: 10.1186/1471-2164-12-34
Source DB: PubMed Journal: BMC Genomics ISSN: 1471-2164 Impact factor: 3.969
Figure 1Characterisation of the transcriptomic response. A; Venn diagram representing mRNA transcripts differentially expressed over control during PGN-O111:B4 and PGN-K12 challenges throughout the time (early, median and late stage). The area of the circles is scaled to the number of transcripts (one way ANOVA p < 0.01) and the fold change (FC >2) expressed in each stage. Black circles: 69, 130, 86 number of transcripts differentially expressed under PGN-O111:B4 treatment. White circles: 173, 64, 219 number of transcripts differentially expressed under PGN-K12 challenge.
Summary of selected transcripts expressed after challenges with PGN-O111:B4
| Early | Median | Late | ||||
|---|---|---|---|---|---|---|
| Antigen presenttion | Mean | SD | Mean | SD | Mean | SD |
| MHC class I heavy chain-1 | 4.92 | 2.35 | 3.27 | 1.67 | n/s | n/s |
| Macrophage receptor MARCO | 2.07 | 0.56 | 5.02 | 1.75 | n/s | n/s |
| Cysteine-rich protein 1 | -3.59 | 0.74 | n/s | n/s | n/s | n/s |
| BPI binding protein | n/s | n/s | 11.93 | 5.78 | n/s | n/s |
| Cell adhesion and proliferation | ||||||
| CD166 | 1.79 | 0.35 | 4.99 | 2.97 | 3.06 | 1.48 |
| Cytokines and Chemokines | ||||||
| C-C chemokine receptor type 3 | 4.25 | 3.47 | n/s | n/s | n/s | n/s |
| Chemokine receptor CXCR4 | n/s | n/s | -4.24 | 1.01 | n/s | n/s |
| Cellullar defense response | ||||||
| N-acetylmuramoyl-L-alanine amidase | -1.60 | 0.05 | 1.46 | 0.03 | 1.46 | 0.17 |
| Peroxiredoxin 1-1 | -2.98 | 1.42 | 1.30 | 0.76 | 1.74 | 0.30 |
| Interleukin enhancer-binding factor 3 | n/s | n/s | 2.39 | 1.47 | n/s | n/s |
| TNF decoy receptor | n/s | n/s | 11.42 | 3.86 | 12.09 | 10.98 |
| NF-kappaB inhibitor alpha-3 | n/s | n/s | 9.24 | 6.05 | n/s | n/s |
| Myeloid differentiation primary response | n/s | n/s | n/s | n/s | 1.56 | 0.29 |
| Phosphotyrosine SH2 domain | n/s | n/s | n/s | n/s | 2.86 | 1.17 |
| Procathepsin L-1 | n/s | n/s | 4.11 | 1.67 | n/s | n/s |
| Procathepsin L-2 | n/s | n/s | 3.47 | 1.28 | n/s | n/s |
| Cathepsin B-2 | n/s | n/s | 3.36 | 2.29 | n/s | n/s |
| Cathepsin D-2 | n/s | n/s | 3.99 | 0.25 | n/s | n/s |
| Cathepsin C-1 | n/s | n/s | 3.28 | 1.16 | n/s | n/s |
| Cathepsin C-2 | n/s | n/s | 5.14 | 5.30 | n/s | n/s |
| MAPK/ERK | ||||||
| Serine/threonine-protein kinase 2 | n/s | n/s | 5.03 | 2.65 | n/s | n/s |
| MAPK/ERK kinase kinase 5-1 | n/s | n/s | -1.68 | 0.33 | n/s | n/s |
| C-Jun protein | n/s | n/s | n/s | n/s | 3.99 | 1.62 |
| MAPK/ERK kinase kinase 1-2 | n/s | n/s | n/s | n/s | 1.87 | 0.46 |
| MAPK kinase 9-2 | n/s | n/s | n/s | n/s | 5.78 | 3.73 |
Transcripts represented were firstly selected for expression level (p < 0.01) and then implication in biological processes related to PGN stimulation (immune/inflammatory responses) during PGN-O111:B4. n/s: not signal, Mean: Fold expression average (n = 3), SD: standard deviation.
Summary of selected transcripts expressed after challenges with PGN-K12.
| Early | Median | Late | ||||
|---|---|---|---|---|---|---|
| Antigen presenttion | Mean | SD | Mean | SD | Mean | SD |
| MHC class I heavy chain-1 | 1.6 | 0.3 | 3.8 | 1.1 | 4.1 | 3.9 |
| BPI binding protein | 3.4 | 2.5 | n/s | n/s | 1.5 | 0.6 |
| Macrophage receptor MARCO | n/s | n/s | n/s | n/s | 0.4 | 1.8 |
| Cell adhesion and proliferation | ||||||
| Fibronectin receptor beta | 11.6 | 11.3 | n/s | n/s | n/s | n/s |
| CD2 binding protein 1-1 | 2.9 | 1.1 | n/s | n/s | n/s | n/s |
| Matrix metalloproteinase 9 | 2.0 | 0.7 | n/s | n/s | -4.7 | 1.8 |
| Cytokines and Chemokines | ||||||
| Cytokine receptor gamma chain | 1.7 | 0.5 | n/s | n/s | n/s | n/s |
| CC chemokine SCYA110-1 | n/s | n/s | n/s | n/s | 1.2 | 0.1 |
| Cellullar defense response | ||||||
| TNF receptor associated factor 1 | n/s | n/s | 4.6 | 4.1 | n/s | n/s |
| NF-kappaB inhibitor alpha-1 | 4.6 | 4.3 | n/s | n/s | n/s | n/s |
| Cathepsin C-3 | 2.8 | 2.3 | n/s | n/s | n/s | n/s |
| Cathepsin D-1 | 3.2 | 2.8 | n/s | n/s | 1.6 | 0.5 |
| Cathepsin D-2 | 3.7 | 3.6 | n/s | n/s | n/s | n/s |
| MAPK/ERK | ||||||
| MAPK/ERK kinase kinase 6 | 1.7 | 0.3 | 2.1 | 0.5 | n/s | n/s |
| Serine/threonine-protein kinase 2 | 2.9 | 2.2 | n/s | n/s | -1.2 | 0.1 |
| Tyrosine-protein kinase FRK | n/s | n/s | n/s | n/s | 1.7 | 0.5 |
| Tyrosine-protein kinase SYK | n/s | n/s | n/s | n/s | -2.0 | 1.4 |
| Inflammatory response | ||||||
| Annexin A1-1 | 9.8 | 9.4 | n/s | n/s | 1.4 | 0.3 |
| Microsomal glutathione S-transferase 3 | -1.6 | 0.2 | -1.4 | 0.2 | 1.2 | 0.1 |
| Arachidonate 5-lipoxygenase-1 | -3.4 | 0.4 | n/s | n/s | n/s | n/s |
| Prostaglandine D synthase | 1.3 | 0.1 | n/s | n/s | n/s | n/s |
| Angiotensin I converting enzyme | 0.0 | n/s | n/s | n/s | 1.2 | n/s |
| Cell homeostasis | ||||||
| Metallothionein A | -4.4 | 1.1 | n/s | n/s | 1.4 | 0.2 |
| Heat shock 27 kDa protein-1 | 2.8 | 0.8 | n/s | n/s | -1.8 | 0.6 |
| Heat shock 70 kDa protein 1 | 3.0 | 1.4 | n/s | n/s | -1.7 | 0.4 |
| Glutathione reductase | 2.0 | 0.8 | n/s | n/s | -2.2 | 1.0 |
| Cellular metabolism | ||||||
| Malate dehydrogenase, cytoplasmic | 2.1 | 0.6 | n/s | n/s | n/s | n/s |
| Glucose-6-phosphate isomerase-1 | n/s | n/s | n/s | n/s | 2.4 | 1.7 |
| ATP synthase factor 6 | 2.4 | 1.7 | n/s | n/s | n/s | n/s |
| Transcription | ||||||
| Reverse transcriptase-like-2 | 2.4 | 1.7 | -2.7 | 0.6 | n/s | n/s |
| CCAAT/enhancer binding protein beta | n/s | n/s | 7.0 | 2.6 | 1.4 | 0.5 |
| Chromatin dis-assembly | ||||||
| Transposase-15 | -4.0 | 3.4 | n/s | n/s | -1.3 | 0.3 |
| Transposase-56 | n/s | n/s | -3.4 | 0.5 | n/s | n/s |
| G1/S-specific cyclin D2 | -3.1 | 2.0 | -3.6 | 1.4 | 1.5 | 0.4 |
Transcripts represented were selected for expression level (p < 0.01) and then implication in biological processes related to PGN stimulation (immune/inflammatory responses) during PGN-K12. n/s: no signal. Mean: Fold expression average (n = 3), SD: standard deviation.
Figure 2Qualitative and quantitative representations of biological processes (GO) over represented during challenges. Qualitative and quantitative representations of over expressed GO categories (Chi-square with Yates correction p < 0.05). The corners of the spider-web maps represent biological processes identified in the GO analysis. Different numbers of transcripts were grouped in each biological process. The continuous mark lines (black or grey) represent the different number of transcripts in each biological process. The differences in the shape of the GO pattern (continuous mark line) are due to divergence in the number of transcripts grouped to each Gene Class (biological process) under both PGN challenges; the black line shows the GO pattern for PGN-O111:B4 and the grey line shows the GO pattern for PGN-K12 treatment.
Figure 3Temporal characterisation of the prostaglandin response. Time course response to macrophages stimulated during 0, 30 min, 1, 3, 6, and 12 h with 10 μg/mL of PGN O111:B4 and K12. Experiments were performed in independent groups of PGN-stimulated (n = 3) or control macrophage cultures (n = 9). a) COX-2 and PTGDS mRNA abundance over time in response to PGN-B4 (black bar) or PGN-K12 (white bar). Were observed significative differences in the mRNA abundance between the times and treatments (PGNs) in both genes (two way ANOVA p < 0.01). b) PGE2 and PGD2 release (pg/mL) stimulated by PGN-O111:B4 (black bars), PGN-K12 (white bars) and control (grey bars) into the culture medium (n = 3/treatment). Were observed significative differences in the release between the times and treatments (PGNs or control) by both prostaglandin (two way ANOVAs p < 0,01). The results are presents as fold change relative to 18S abundance and ± std deviation.
Figure 4Concentration dependence of the prostaglandin response. Dose response (0.1, 1, and 10 μg/mL) of trout macrophages to PGN O111:B4 and K12 challenge. Experiments were performed overnight in independent macrophage cultures (n = 3). a) COX-2 and PTGDS mRNA abundance (black bar) in response to different doses of PGN-O111:B4 or PGN-K12 (0.1, 1, 10 μg/mL). Were observed significative differences in the mRNA abundance between different doses and treatments (PGNs) in both genes (two way ANOVAs p < 0.01). b) PGE2 and PGD2 release (pg/mL) into the culture medium (grey bars). Were observed significative differences in the release between doses and treatments (PGNs or control) by both prostaglandins (two way ANOVAs p < 0.01). The results are presented as fold change relative to 18S abundance and mean ± std deviation.